Does the media refer more to NTRA or BMRN?

In the previous week, Natera had 4 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 15 mentions for Natera and 11 mentions for BioMarin Pharmaceutical. Natera's average media sentiment score of 0.97 beat BioMarin Pharmaceutical's score of 0.63 indicating that Natera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 8 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BioMarin Pharmaceutical 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RVMD or BMRN?

In the previous week, Revolution Medicines had 11 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 22 mentions for Revolution Medicines and 11 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.63 beat Revolution Medicines' score of 0.61 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 12 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BIIB or BMRN?

In the previous week, Biogen had 9 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 20 mentions for Biogen and 11 mentions for BioMarin Pharmaceutical. Biogen's average media sentiment score of 0.90 beat BioMarin Pharmaceutical's score of 0.63 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 7 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ROIV or BMRN?

In the previous week, BioMarin Pharmaceutical had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for BioMarin Pharmaceutical and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.91 beat BioMarin Pharmaceutical's score of 0.63 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioMarin Pharmaceutical (BMRN) Competitors

$63.94 -1.14 (-1.75%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$63.90 -0.04 (-0.06%)

As of 09/18/2026 07:30 PM Eastern

Compare

BMRN vs. NTRA, RVMD, ALNY, BIIB, and ROIV

Should you buy BioMarin Pharmaceutical stock or one of its competitors? BioMarin Pharmaceutical's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), and Roivant Sciences (ROIV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioMarin Pharmaceutical compare to Natera?

Natera (NASDAQ:NTRA) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Natera's net margin of -7.11%. BioMarin Pharmaceutical's return on equity of 5.32% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

BioMarin Pharmaceutical has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	23.09	-$208.16M	-$1.36	N/A
BioMarin Pharmaceutical	$3.22B	3.84	$348.90M	$0.37	172.81

99.9% of Natera shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Natera had 4 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 15 mentions for Natera and 11 mentions for BioMarin Pharmaceutical. Natera's average media sentiment score of 0.97 beat BioMarin Pharmaceutical's score of 0.63 indicating that Natera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Natera presently has a consensus target price of $330.83, suggesting a potential downside of 10.44%. BioMarin Pharmaceutical has a consensus target price of $89.17, suggesting a potential upside of 39.46%. Given BioMarin Pharmaceutical's higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70

Summary

Natera beats BioMarin Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, Revolution Medicines had 11 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 22 mentions for Revolution Medicines and 11 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.63 beat Revolution Medicines' score of 0.61 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	12 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Revolution Medicines' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

BioMarin Pharmaceutical has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,534.39	-$1.13B	-$8.82	N/A
BioMarin Pharmaceutical	$3.22B	3.84	$348.90M	$0.37	172.81

Revolution Medicines presently has a consensus price target of $226.17, indicating a potential upside of 18.44%. BioMarin Pharmaceutical has a consensus price target of $89.17, indicating a potential upside of 39.46%. Given BioMarin Pharmaceutical's higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70

Summary

BioMarin Pharmaceutical beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to BioMarin Pharmaceutical's net margin of 2.14%. Alnylam Pharmaceuticals' return on equity of 84.93% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Alnylam Pharmaceuticals presently has a consensus price target of $367.20, suggesting a potential upside of 53.28%. BioMarin Pharmaceutical has a consensus price target of $89.17, suggesting a potential upside of 39.46%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Alnylam Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.87
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alnylam Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

BioMarin Pharmaceutical has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.63	$313.75M	$5.38	44.53
BioMarin Pharmaceutical	$3.22B	3.84	$348.90M	$0.37	172.81

In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 12 mentions for Alnylam Pharmaceuticals and 11 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.63 beat Alnylam Pharmaceuticals' score of 0.14 indicating that BioMarin Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
BioMarin Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alnylam Pharmaceuticals beats BioMarin Pharmaceutical on 13 of the 17 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Biogen?

Biogen (NASDAQ:BIIB) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Biogen currently has a consensus target price of $230.14, suggesting a potential upside of 6.79%. BioMarin Pharmaceutical has a consensus target price of $89.17, suggesting a potential upside of 39.46%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe BioMarin Pharmaceutical is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70

Biogen has a net margin of 8.32% compared to BioMarin Pharmaceutical's net margin of 2.14%. Biogen's return on equity of 11.18% beat BioMarin Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

87.9% of Biogen shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Biogen has higher revenue and earnings than BioMarin Pharmaceutical. Biogen is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.22	$1.29B	$5.65	38.14
BioMarin Pharmaceutical	$3.22B	3.84	$348.90M	$0.37	172.81

Biogen has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

In the previous week, Biogen had 9 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 20 mentions for Biogen and 11 mentions for BioMarin Pharmaceutical. Biogen's average media sentiment score of 0.90 beat BioMarin Pharmaceutical's score of 0.63 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	7 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Biogen beats BioMarin Pharmaceutical on 9 of the 16 factors compared between the two stocks.

How does BioMarin Pharmaceutical compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Roivant Sciences' net margin of -3,534.96%. BioMarin Pharmaceutical's return on equity of 5.32% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Roivant Sciences currently has a consensus price target of $45.64, suggesting a potential upside of 14.75%. BioMarin Pharmaceutical has a consensus price target of $89.17, suggesting a potential upside of 39.46%. Given BioMarin Pharmaceutical's higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

BioMarin Pharmaceutical has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,477.80	-$299.77M	-$0.53	N/A
BioMarin Pharmaceutical	$3.22B	3.84	$348.90M	$0.37	172.81

In the previous week, BioMarin Pharmaceutical had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for BioMarin Pharmaceutical and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.91 beat BioMarin Pharmaceutical's score of 0.63 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	3 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioMarin Pharmaceutical beats Roivant Sciences on 11 of the 16 factors compared between the two stocks.

Get BioMarin Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMRN vs. The Competition

Export

Metric	BioMarin Pharmaceutical	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.38B	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	172.81	14.23	275.49	25.40
Price / Sales	3.84	1,440.84	644.44	86.30
Price / Cash	22.41	108.90	76.25	51.42
Price / Book	2.02	15.45	10.46	6.33
Net Income	$348.90M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-2.65%	-1.21%	0.59%	1.12%
1 Month Performance	-5.53%	-3.29%	-1.74%	-2.39%
1 Year Performance	17.62%	37.74%	18.13%	5.35%

BioMarin Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMRN BioMarin Pharmaceutical	4.6176 of 5 stars	$63.94 -1.8%	$89.17 +39.5%	+17.6%	$12.38B	$3.22B	172.81	3,221	Analyst Forecast High Trading Volume
NTRA Natera	1.8057 of 5 stars	$327.16 +0.3%	$330.83 +1.1%	+104.0%	$47.28B	$2.31B	N/A	6,140
RVMD Revolution Medicines	3.2624 of 5 stars	$203.27 0.0%	$218.11 +7.3%	+338.6%	$43.57B	$11.58M	N/A	883	Trending News Insider Trade
ALNY Alnylam Pharmaceuticals	4.4581 of 5 stars	$252.62 +2.1%	$376.67 +49.1%	-47.2%	$33.85B	$3.71B	47.01	2,770
BIIB Biogen	3.4915 of 5 stars	$217.63 +1.0%	$230.14 +5.8%	+51.2%	$32.19B	$9.89B	38.56	7,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMRN) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioMarin Pharmaceutical (BMRN) Competitors

BMRN vs. NTRA, RVMD, ALNY, BIIB, and ROIV

How does BioMarin Pharmaceutical compare to Natera?

Summary

How does BioMarin Pharmaceutical compare to Revolution Medicines?

Summary

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Summary

How does BioMarin Pharmaceutical compare to Biogen?

Summary

How does BioMarin Pharmaceutical compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN vs. The Competition

BioMarin Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioMarin Pharmaceutical (BMRN) Competitors

BMRN vs. NTRA, RVMD, ALNY, BIIB, and ROIV

How does BioMarin Pharmaceutical compare to Natera?

Is NTRA or BMRN more profitable?

Which has preferable valuation & earnings, NTRA or BMRN?

Do insiders & institutionals have more ownership in NTRA or BMRN?

Does the media refer more to NTRA or BMRN?

Which has more volatility & risk, NTRA or BMRN?

Do analysts recommend NTRA or BMRN?

Summary

How does BioMarin Pharmaceutical compare to Revolution Medicines?

Does the media favor RVMD or BMRN?

Which has more risk and volatility, RVMD or BMRN?

Do insiders & institutionals have more ownership in RVMD or BMRN?

Is RVMD or BMRN more profitable?

Which has preferable earnings & valuation, RVMD or BMRN?

Do analysts rate RVMD or BMRN?

Summary

How does BioMarin Pharmaceutical compare to Alnylam Pharmaceuticals?

Is ALNY or BMRN more profitable?

Do analysts prefer ALNY or BMRN?

Do insiders and institutionals hold more shares of ALNY or BMRN?

Which has more risk and volatility, ALNY or BMRN?

Which has preferable earnings and valuation, ALNY or BMRN?

Does the media favor ALNY or BMRN?

Summary

How does BioMarin Pharmaceutical compare to Biogen?

Do analysts prefer BIIB or BMRN?

Is BIIB or BMRN more profitable?

Do insiders & institutionals hold more shares of BIIB or BMRN?

Which has better valuation and earnings, BIIB or BMRN?

Which has more volatility and risk, BIIB or BMRN?

Does the media favor BIIB or BMRN?

Summary

How does BioMarin Pharmaceutical compare to Roivant Sciences?

Is ROIV or BMRN more profitable?

Do analysts recommend ROIV or BMRN?

Do institutionals and insiders believe in ROIV or BMRN?

Which has more risk and volatility, ROIV or BMRN?

Which has preferable earnings and valuation, ROIV or BMRN?

Does the media refer more to ROIV or BMRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMRN vs. The Competition

BioMarin Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools